Neurocrine Biosciences (NBIX) Expected to Announce Quarterly Earnings on Tuesday

Neurocrine Biosciences (NASDAQ:NBIX) is anticipated to announce its Q3 2025 results after the market closes on Tuesday, October 28th. Analysts expect the company to announce earnings of $1.55 per share and revenue of $746.6050 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, October 28, 2025 at 4:30 PM ET.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.98 by $0.08. The firm had revenue of $687.50 million for the quarter, compared to the consensus estimate of $653.09 million. Neurocrine Biosciences had a return on equity of 13.22% and a net margin of 13.88%.The company’s quarterly revenue was up 16.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.63 earnings per share. On average, analysts expect Neurocrine Biosciences to post $4 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Trading Up 0.9%

NBIX opened at $141.33 on Tuesday. The company has a market cap of $14.02 billion, a P/E ratio of 41.81, a P/E/G ratio of 1.01 and a beta of 0.21. The business’s 50-day moving average price is $139.00 and its 200-day moving average price is $126.56. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $154.61.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 106,322 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the sale, the director directly owned 514,596 shares of the company’s stock, valued at approximately $65,050,080.36. The trade was a 17.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.80% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Hedge funds have recently made changes to their positions in the stock. Sivia Capital Partners LLC bought a new stake in shares of Neurocrine Biosciences in the 2nd quarter worth approximately $215,000. State of Wyoming boosted its position in shares of Neurocrine Biosciences by 71.2% in the 2nd quarter. State of Wyoming now owns 1,671 shares of the company’s stock worth $210,000 after purchasing an additional 695 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Neurocrine Biosciences in the 1st quarter worth approximately $1,333,000. Finally, Headlands Technologies LLC boosted its position in shares of Neurocrine Biosciences by 256.5% in the 2nd quarter. Headlands Technologies LLC now owns 6,852 shares of the company’s stock worth $861,000 after purchasing an additional 4,930 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NBIX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. boosted their price target on Neurocrine Biosciences from $140.00 to $145.00 and gave the company a “neutral” rating in a report on Thursday, July 31st. Truist Financial initiated coverage on Neurocrine Biosciences in a report on Monday, July 21st. They set a “buy” rating and a $163.00 price target on the stock. Needham & Company LLC boosted their price target on Neurocrine Biosciences from $161.00 to $170.00 and gave the company a “buy” rating in a report on Monday, September 22nd. Morgan Stanley boosted their price target on Neurocrine Biosciences from $163.00 to $168.00 and gave the company an “overweight” rating in a report on Monday. Finally, Wall Street Zen upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $163.72.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.